China Solid Tumor NPP Lead

Job description

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at jnj.com. As guided by Our Credo, Johnson & Johnson is responsible to our employees who work with us throughout the world. We provide an inclusive work environment where each person is considered as an individual. At Johnson & Johnson, we respect the diversity and dignity of our employees and recognize their merit. Job Function: Marketing Job Sub Function: Strategic Marketing Job Category: People Leader All Job Posting Locations: Beijing, China, Shanghai, China Job Description: Job Title: Solid Tumor China NPP Lead Reporting LineReports to: APSO Solid Tumor TA Lead Matrix collaboration with: APSO, OpCo Solid Tumors teams, China R&D (CCT), Medical, Market Access, BD, and Commercial Operations Purpose of the RoleThe China Solid Tumors Strategic Marketing – New Product Planning Lead is accountable for shaping and driving the long‑term pipeline and portfolio strategy for Solid Tumour oncology in China, from early clinical stages through pre‑launch readiness. This role serves as the strategic “bridge” between global asset development and China’s unique market needs, ensuring future assets, indications, and business models are fit‑for‑China, competitively differentiated, and launch‑ready. The role leads China NPP strategy across key solid tumour disease areas and plays a critical role in influencing global development priorities, lifecycle strategy, and portfolio investment decisions. Key Responsibilities1. China Solid Tumours Pipeline & Portfolio StrategyOwn and drive the China Solid Tumours NPP strategy, spanning early to late‑stage assets and indications. Define China‑specific strategic imperatives, disease area priorities, and portfolio sequencing aligned to unmet medical need and commercial opportunity. Lead pipeline sufficiency and portfolio gap analysis versus current and future competitive landscapes in China. Develop and articulate clear China value narratives for pipeline assets to support governance, prioritization, and investment decisions. 2. Early Asset & Indication ShapingInfluence Target Product Profiles (TPPs), indication sequencing, and clinical development strategies to optimize China relevance. Partner closely with China Compound Team (CCT), APSO DAS lead, and Medical Affairs to ensure early integration of commercial insights. Provide strategic input at key global development milestones (pre‑IND, Phase I–III, lifecycle extensions). Identify China‑specific opportunities including biomarkers, precision medicine strategies, combination approaches, and novel access models. 3. Pre‑Launch & Launch Excellence ReadinessLead China pre‑launch strategic planning for priority solid tumour assets, ensuring seamless transition from NPP to inline teams. Define future launch archetypes, success metrics, and critical enablers (diagnostics, patient pathways, ecosystem readiness). Ensure early alignment across Commercial, Medical, Market Access, and Operations on launch ambition and execution model. 4. Cross‑Functional & Global LeadershipAct as the China strategic interface to global and regional Solid Tumours teams. Lead and influence complex, matrixed cross‑functional teams without direct authority. Partner with Business Development to assess external opportunities, collaborations, and pipeline expansion options relevant to China. Represent China perspectives in global governance forums, ensuring China’s voice is clearly articulated and influential. 5. Strategic Planning & GovernanceDrive China Solid Tumours long‑range strategic planning (LRFP, BP) from a pipeline and portfolio perspective. Support senior leadership with high‑quality strategic insights, scenario planning, and decision frameworks. Ensure all activities are compliant with internal governance, ethics, and regulatory requirements. Key StakeholdersAP Solid Tumours DAS & Asset Teams China Oncology Leadership Team China R&D / CCT Medical Affairs, Market Access, Commercial Excellence Business Development & Strategic Insights Qualifications & ExperienceRequiredBachelor’s degree required; MBA, PhD, PharmD, or MD strongly preferred Extensive experience in oncology strategic marketing, NPP, portfolio strategy, or commercial strategy Strong understanding of China oncology market dynamics, including policy, access, and competitive environment Proven ability to influence global development and lifecycle strategy without direct reporting lines Experience across early and late‑stage pipeline assets PreferredSolid tumour therapeutic area expertise (e.g., lung, GU, GI, bladder, CRC, breast, head & neck) Experience working in matrixed global–regional–local organizations Exposure to precision medicine, diagnostics, or novel modalities Strong strategic storytelling and executive communication skills Critical CapabilitiesEnterprise‑level strategic thinking Strong commercial and clinical acumen High influence and stakeholder management capability Comfort with ambiguity and early‑stage decision‑making Ability to translate complexity into clear strategic choices Success MeasuresStrength and clarity of China Solid Tumours pipeline strategy Degree of China influence on global asset and indication decisions Quality of pre‑launch readiness for priority assets Leadership impact across cross‑functional and global stakeholders Required Skills: Preferred Skills: Brand Marketing, Brand Marketing, Brand Positioning Strategy, Business Alignment, Business Storytelling, Business Valuations, Cross-Functional Collaboration, Customer Intelligence, Data Analysis, Data-Driven Decision Making, Developing Others, Digital Strategy, Execution Focus, Financial Analysis, Go-to-Market Strategies, Inclusive Leadership, Industry Analysis, Leadership, Market Research, Negotiation, Problem Solving, Product Development Lifecycle, Product Portfolio Management, Product Strategies, Program Management {+ 2 more}